Immunotherapy Strategy Could Be Beneficial for Relapsed Acute … – Newswise (press release)
|
Immunotherapy Strategy Could Be Beneficial for Relapsed Acute …
Newswise (press release) Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on Saturday, Dec. 9. |
